Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial

作者：Timothy F. Cloughesy, Martin J. van den Bent, Mehdi Touat, Deborah T. Blumenthal, Katherine B. Peters, Benjamin M. Ellingson, Jennifer Clarke, Joe Mendez, Shlomit Yust‐Katz, Liam Welsh, Warren Mason, François Ducray, Yoshie Umemura, Burt Nabors, Matthias Holdhoff, Andreas F. Hottinger, Yoshiki Arakawa, Juan Manuel Sepúlveda-Sánchez, Wolfgang Wick, Riccardo Soffietti, James Perry, Pierre Giglio, Macarena de la Fuente, Elizabeth A. Maher, Andrew Bottomley, Adriana E. Tron, Denise Yi, Dan Zhao, Shuchi S. Pandya, Lori Steelman, Islam Hassan, Patrick Y. Wen, Ingo K. Mellinghoff · 发表于：The Lancet Oncology · 年份：2025 · DOI：10.1016/s1470-2045(25)00472-3 · 被引用次数：27 · 研究领域：Glioma Diagnosis and Treatment、Hedgehog Signaling Pathway Studies、Chromatin Remodeling and Cancer